{"corpus_id":252457006,"paper_sha":"83a5ef54eb7a7115c0bf308ca6e653cac5c76872","doi":"10.3390/vaccines10091546","arxiv_id":null,"pmid":36146624,"pmcid":"9506411","mag_id":null,"dblp_id":null,"acl_id":null,"title":"An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results","year":2022,"publication_date":"2022-09-01","venue":"Vaccines","journal":{"name":"Vaccines","pages":null,"volume":"10"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":96,"citation_count":2,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":null,"chemicals":null,"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.mdpi.com/2076-393X/10/9/1546/pdf?version=1663726696","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/83a5ef54eb7a7115c0bf308ca6e653cac5c76872","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"This study aimed to assess the magnitude of anti-SARS-CoV-2 immunoglobulin G (IgG) titers and Interferon-Gamma Release Assay (IGRA) test results following administration of booster BNT162b2 in 48 ChAd-primed participants (vaccination schedule: ChAd/ChAd/BNT). Whole blood samples were collected: first, before and second, 21 days after the booster dose. The IgG level was measured using chemiluminescent immunoassay; the intensity of the T-cell response—IFNγ concentration—was assessed using IGRA test. At 21 days after the booster, all subjects achieved reactive/positive anti-SARS-CoV-2 IgG, and IGRA test results showed a significant increase compared to the results before booster administration. We compared the results before and after the booster between participants with and without prior history of COVID-19. The IFNγ concentrations in both cohorts were higher in convalescents (both before booster and 21 days after). The IgG titers were subtly lower in COVID-19 convalescents than in naïve but without statistical significance. Data on cell-mediated immunity are scarce, especially with regard to the general population. A better understanding of the complexity of the immune response to SARS-CoV-2 could contribute to developing more effective vaccination strategies.","claims":[{"public_id":"cl_bad18e713ec7982ecca07263f7ebae64","status":"active","text":"At 21 days after BNT162b2 booster administration in 48 ChAd/ChAd/BNT-vaccinated participants, all subjects achieved reactive/positive anti-SARS-CoV-2 IgG titers.","confidence":0.95,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_bad18e713ec7982ecca07263f7ebae64"},{"public_id":"cl_978f041afe5013ab913756dfeff96caa","status":"active","text":"IFNγ concentrations were higher in COVID-19 convalescents than in naïve participants at both timepoints—before and 21 days after the BNT162b2 booster.","confidence":0.92,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_978f041afe5013ab913756dfeff96caa"},{"public_id":"cl_d000129c721da44773f8ccc1ac734a0c","status":"active","text":"IGRA test results showed a significant increase at 21 days after the BNT162b2 booster compared to pre-booster values in ChAd-primed participants.","confidence":0.93,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_d000129c721da44773f8ccc1ac734a0c"},{"public_id":"cl_500343cdfe9245119e0b19a4bbde413f","status":"active","text":"IgG titers were subtly lower in COVID-19 convalescents than in naïve participants after the booster dose, but the difference was not statistically significant.","confidence":0.88,"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/claims/cl_500343cdfe9245119e0b19a4bbde413f"}],"concepts":[{"public_id":"co_0ca15246c0c120a4b5e953b2c5c80479","status":"active","name":"COVID-19 convalescents","description":"Study participants who had a prior documented COVID-19 infection before enrollment, forming one of the two comparison cohorts for immune response analysis.","types":["participant group"],"aliases":["convalescents","COVID-19 recovered participants"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_0ca15246c0c120a4b5e953b2c5c80479"},{"public_id":"co_0fc296ec4b20f8e6c2d9e62c9e388a11","status":"active","name":"chemiluminescent immunoassay","description":"A laboratory technique used in this study to quantify anti-SARS-CoV-2 IgG levels in participant serum samples.","types":["measurement technique"],"aliases":["CLIA"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_0fc296ec4b20f8e6c2d9e62c9e388a11"},{"public_id":"co_2a02622c72b0eda2353a658039cc49de","status":"active","name":"cell-mediated immunity","description":"T-cell-based immune responses evaluated here via IGRA to characterize SARS-CoV-2-specific cellular immunity following heterologous booster vaccination.","types":["immune mechanism"],"aliases":["T-cell response","cellular immunity"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_2a02622c72b0eda2353a658039cc49de"},{"public_id":"co_2b1cbac5fc78275535a7bd59e4ee198b","status":"active","name":"interferon-gamma","description":"A cytokine released by sensitized T cells upon antigen stimulation, measured here as the primary IGRA readout to quantify T-cell immune responses to SARS-CoV-2 vaccination.","types":["cytokine","biomarker"],"aliases":["IFNγ","IFN-gamma"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_2b1cbac5fc78275535a7bd59e4ee198b"},{"public_id":"co_64a7fc4ce9b439d8b53960a54e0b374b","status":"active","name":"anti-SARS-CoV-2 immunoglobulin G","description":"Serum IgG antibodies directed against SARS-CoV-2 antigens, measured here by chemiluminescent immunoassay to evaluate humoral immune response after heterologous booster vaccination.","types":["antibody","biomarker"],"aliases":["anti-SARS-CoV-2 IgG","anti-RBD IgG"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_64a7fc4ce9b439d8b53960a54e0b374b"},{"public_id":"co_8f85fb6c49c7352b2bc6729086011db4","status":"active","name":"BNT162b2","description":"An mRNA-based COVID-19 vaccine developed by Pfizer-BioNTech, administered here as the heterologous booster dose following ChAdOx1 primary vaccination.","types":["vaccine"],"aliases":["Pfizer-BioNTech mRNA vaccine"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_8f85fb6c49c7352b2bc6729086011db4"},{"public_id":"co_afedb8596f96002a387dd2c987e64c3b","status":"active","name":"heterologous ChAdOx1/BNT162b2 vaccination","description":"A mixed COVID-19 vaccination strategy in which two ChAdOx1 primary doses are followed by a BNT162b2 booster, designated ChAd/ChAd/BNT in this study.","types":["vaccination strategy"],"aliases":["ChAd/ChAd/BNT","heterologous vaccination schedule"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_afedb8596f96002a387dd2c987e64c3b"},{"public_id":"co_b437a3300a0a05fd0e5fea3a26172e89","status":"active","name":"booster dose","description":"A third vaccine dose—BNT162b2 in this study—administered to ChAd/ChAd-primed participants to augment immune protection against COVID-19.","types":["intervention"],"aliases":["third dose","booster"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_b437a3300a0a05fd0e5fea3a26172e89"},{"public_id":"co_b7fa485a6d9d8acf9505579dbdcfc698","status":"active","name":"ChAdOx1","description":"An adenoviral vector-based COVID-19 vaccine used as the two-dose primary series in the heterologous ChAd/ChAd/BNT schedule studied here.","types":["vaccine"],"aliases":["ChAd","AstraZeneca vaccine"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_b7fa485a6d9d8acf9505579dbdcfc698"},{"public_id":"co_f9502c5d896e56833114651ad9d82974","status":"active","name":"Interferon-Gamma Release Assay","description":"A whole-blood test that quantifies IFNγ released by antigen-stimulated T cells, used here to assess SARS-CoV-2-specific cell-mediated immunity before and after the booster dose.","types":["diagnostic test","measurement technique"],"aliases":["IGRA"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"url":"https://sah.borca.ai/concepts/co_f9502c5d896e56833114651ad9d82974"}],"external_ids":{"DOI":"10.3390/vaccines10091546","ArXiv":null,"PubMed":36146624,"PubMedCentral":"9506411","MAG":null,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.mdpi.com/2076-393X/10/9/1546/pdf?version=1663726696","landing_url":"https://www.semanticscholar.org/paper/83a5ef54eb7a7115c0bf308ca6e653cac5c76872","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":630964,"paper_uid":"694cfb0f-8290-4ea2-acde-13b0c84ca619","canonical_identity":{"paper_id":630964,"paper_uid":"694cfb0f-8290-4ea2-acde-13b0c84ca619","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/252457006"}